← back to search

A. Craig Lockhart

Medical University of South Carolina · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, and Gastric Cancer Management and Outcomes.
h-index
43
citations
9,152
works
283
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
2025cited by 3position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025cited by 0position: contributordoi
Supplementary Figures from Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer
2025cited by 0position: contributordoi
Data from Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer
2025cited by 0position: contributordoi
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer
npj Precision Oncology 2024cited by 8position: middledoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2023cited by 0position: contributordoi
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
2022cited by 86position: contributordoi
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Clinical Cancer Research 2021cited by 41position: middledoi
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer
Oncogene 2021cited by 36position: middledoi
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Investigational New Drugs 2021cited by 33position: middledoi
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
Oncogene 2021cited by 22position: middledoi
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician
JCO Precision Oncology 2021cited by 14position: lastdoi
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
The Lancet Oncology 2020cited by 189position: middledoi
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
Nature Communications 2020cited by 129position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David M. Hyman · Mayo Clinic in Florida4 papers (2016–2020)Haeseong Park · Harvard University4 papers (2017–2020)Katrina S. Pedersen · Mayo Clinic in Arizona4 papers (2017–2021)José Baselga · Vall d'Hebron Institute of Oncology4 papers (2014–2020)Andrea Wang‐Gillam · Washington University in St. Louis4 papers (2017–2021)Ian Chau · Royal Marsden NHS Foundation Trust4 papers (2017–2020)Benjamin Tan · National University Hospital4 papers (2017–2021)Bethany Pitcher · Princess Margaret Cancer Centre3 papers (2017–2020)Joanne Xiu · Enzo Life Sciences (United States)3 papers (2021–2024)Kian‐Huat Lim · Brown University3 papers (2017–2020)Richard M. Goldberg · West Virginia University Hospitals3 papers (2021–2024)David B. Lombard · University of Miami3 papers (2025–2025)Antoine Hollebecque · Institut Gustave Roussy3 papers (2018–2018)Peter C. Enzinger · Harvard University3 papers (2018–2018)Jimmy J. Hwang · Levine Cancer Institute3 papers (2021–2024)Todd Riehl · Gene Therapy Laboratory3 papers (2017–2020)Deukwoo Kwon · Icahn School of Medicine at Mount Sinai3 papers (2025–2025)Janaki Sharma · University of Miami3 papers (2025–2025)Priyamvada Rai · University of Miami School of Medicine3 papers (2025–2025)— · 3 papers (2025–2025)